Key result
Targeting serotonin synthesis or signaling shows promise for developing novel PAH therapies.
Why the study?
Serotonin synthesis is elevated in PAH and associated with its pathologies, making targeting serotonin synthesis or signaling a promising approach for novel therapies.
Design
Review
Authors
Loading...
Should not yet alter PAH management; leaves open whether TPH1 or 5-HT1B inhibition improves outcomes in trials.
This review highlights the pathogenic role of serotonin in pulmonary arterial hypertension and suggests targeting its synthesis or signaling as a promising therapeutic strategy.
MacLean et al. (2022) conducted a review in Pulmonary arterial hypertension. Targeting serotonin synthesis or signaling was evaluated. Targeting serotonin synthesis or signaling is a promising approach that may lead to novel therapies for pulmonary arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: